Clinical-stage company with substantial research and development spending, no reported product revenue in 2025, and net losses of $166,308,000 in 2025 and $80,488,000 in 2024.

# Unnamed Company

Document: PART I of a Form 10-K

Sections and page numbers:
- Item 1. Business — page 5
- Item 1A. Risk Factors — page 62
- Item 1B. Unresolved Staff Comments — page 136
- Item 1C. Cybersecurity — page 136
- Item 2. Properties — page 138
- Item 3. Legal Proceedings — page 138
- Item 4. Mine Safety Disclosures — page 139

Inferences from the structure:
- The document follows the Form 10-K annual report format.
- The inclusion of Mine Safety Disclosures indicates the company operates in an industry where mine safety is relevant (for example, mining or related sectors).

Next step:
- Please provide the text from Item 1. Business (and any other sections you want included). With that content I can produce a detailed markdown summary covering the company’s operations and key metrics (customers, employees, revenue, income).

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs in cancer treatment, with a lead product candidate furmonertinib targeting non-small cell lung cancer.

# Summary of Arrivent Biopharma, Inc.

### Company Overview
Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for unmet medical needs, primarily focusing on patients with cancers. Their lead product candidate, furmonertinib, is a novel EGFR mutant-selective tyrosine kinase inhibitor currently being evaluated in clinical trials for various mutations associated with non-small cell lung cancer (NSCLC).

---

### Key Details

- **Founded**: 2021
- **Headquarters**: 18 Campus Boulevard Suite 100, Newtown Square, PA 19073
- **Number of Employees**: 40 (as of December 31, 2023)
  - 30 employees in research and development, including 22 with Ph.D. or M.D. degrees.
  
### Products and Pipeline

- **Lead Product Candidate**: 
  - **Furmonertinib**
    - **Indications**: Primarily targeting NSCLC with a specific focus on patients with uncommon epidermal growth factor receptor mutations (e.g., exon 20 insertions and P-loop alpha-c helix compressing (PACC) mutations).
    - **Current Status**: 
      - Ongoing pivotal Phase 3 clinical trial (FURVENT) for first-line treatment in non-squamous locally advanced or metastatic NSCLC patients with exon 20 insertion mutations.
      - Completed Phase 3 trial in China, leading to approval by the National Medical Products Administration for first-line use in classical EGFR mutations.
        
### Financial Details

- **Revenue**: Arrivent has not generated revenue since its inception, as it is still in the clinical development phase.
- **Operating Losses**: 
  - $69.3 million for the fiscal year ended December 31, 2023.
  - $36.9 million for the fiscal year ended December 31, 2022.
- **Cumulative Losses**: Accumulated deficit of approximately $157.8 million as of December 31, 2023.

### Market Strategy

- **Target Market**: Focused on lung cancer, which poses a significant global health burden. NSCLC represents about 85% of lung cancer diagnoses, with EGFR mutations being one of the most common drivers, affecting a significant portion of patients.
- **Business Development**: Arrivent seeks to engage in strategic collaborations to bolster its pipeline and enhance its market offerings, especially in areas currently underserved by existing therapies.

### Customers and Market

- **Number of Customers**: As a clinical-stage company, Arrivent does not have customers in the traditional sense since it has not launched any products commercially. Once furmonertinib is approved, the target market will include healthcare providers and patients diagnosed with NSCLC.
- **Future Plans**: The company aims to expand its R&D pipeline through partnerships, licensing agreements, and the development of additional product candidates.

---

Overall, Arrivent Biopharma is focused on maximizing the potential of furmonertinib and advancing toward regulatory approvals and commercialization, while navigating significant financial challenges as a clinical-stage entity.

ArriVent BioPharma, Inc.

10-K / March 5, 2026

10-K / March 28, 2024

10-K / March 5, 2026

Unnamed Company